z-logo
Premium
Growth hormone deficiency after childhood bone marrow transplantation with total body irradiation: interaction with adiposity and age
Author(s) -
Davis N.L.,
Stewart C.E.,
Moss A.D.,
Woltersdorf W.W.W.,
Hunt L.P.,
Elson R.A.,
Cornish J.M.,
Stevens M.C.G.,
Crowne E.C.
Publication year - 2015
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12773
Subject(s) - medicine , short stature , total body irradiation , growth hormone deficiency , endocrinology , bone age , insulin tolerance test , growth hormone , area under the curve , transplantation , hormone , insulin , insulin resistance , chemotherapy , insulin sensitivity , cyclophosphamide
Summary Objective Bone marrow transplantation with total body irradiation ( BMT / TBI ) has adverse effects on growth, growth hormone status and adiposity. We investigated the GH – IGF ‐ I axis in relation to adiposity. Design Cross‐sectional case control study. Patients BMT / TBI survivors ( n  = 22) and short stature control participants ( n  = 19), all GH ‐naïve or off GH treatment >3 months. Measurements Auxology, DEXA scans and GH – IGF ‐ I axis investigation: (i) 12‐h overnight GH profiles; (ii) insulin tolerance test ( ITT ); and (iii) IGF ‐ I generation test. Analysis: auto‐deconvolution of GH profile data and comparison of quantitative parameters using anova . Results Eighty‐two percent of BMT / TBI survivors had growth hormone deficiency ( GHD ) using ITT . GH profile area‐under‐the‐curve ( GH ‐ AUC ) was reduced in BMT / TBI survivors vs short stature control participants [geometric mean (range) 209 (21–825) vs 428 (64–1400) mcg/l/12 h, respectively, P  =   0·007]. GHD was more marked in those who had additional cranial irradiation ( CRT ) [ ITT peak 1·4 (0·2–3·0) vs TBI only 4·1 (1·1–14·8) mcg/l, P  = 0·036]. GHD was more marked at the end of growth in BMT / TBI survivors vs short stature control participants ( GH ‐ AUC 551 (64–2474) vs 1369 (192–4197) mcg/l/12 h, respectively, P  = 0·011) and more prevalent (9/11 vs 1/9, respectively, P  = 0·005). GH profile data were consistent with ITT results in 80% of participants. IGF ‐ I generation tests were normal. BMT / TBI survivors still demonstrated lower GH levels after adjustment for adiposity (fat‐adjusted mean difference for GH ‐ AUC 90·9 mcg/l/12 h, P  = 0·025). Conclusions GHD was more prevalent in BMT / TBI survivors than expected for the CRT dose in TBI , worsened with time and persisted into adulthood. GHD could not be explained by adiposity. There was no evidence of GH neurosecretory dysfunction or resistance after BMT / TBI .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom